Is It Safe to Take Wegovy for Weight Loss?

Wegovy (semaglutide 2.4 mg once weekly) has been through some of the largest clinical trials ever conducted for a weight-loss drug, and the overall safety profile is well characterized. Data from the STEP trial program show it is generally well tolerated, with the most common side effects being gastrointestinal and typically mild to moderate in severity.¹ But “generally safe” does not mean risk-free, and a more honest answer depends on who you are, how long you plan to take it, and which specific risks you care about most.

What the Most Common Side Effects Look Like

The side effects that affect the most people are all gastrointestinal: nausea, vomiting, diarrhea, and constipation. These are not incidental. They stem from the drug’s core mechanism. Semaglutide mimics a gut hormone called GLP-1, which slows the speed at which your stomach empties. That slowing is actually part of how the drug works to reduce appetite, but it also means your digestive system takes a while to adjust.²

In clinical trials, these symptoms were most common during the dose-escalation phase, when you are slowly ramping up from a low dose to the full 2.4 mg. For most people, nausea and other GI complaints faded over time and rarely led to permanent discontinuation of the drug.¹ Still, a meaningful number of people find the GI effects unpleasant enough to stop. Real-world data from an academic obesity clinic found that about half of patients had discontinued semaglutide or tirzepatide within 12 months, with GI intolerance being a common reason.³

One practical tip: skipping the gradual dose increases is a bad idea. A published case report described a patient who resumed semaglutide at the full 2 mg dose without titrating back up and developed gastroparesis, a condition where the stomach essentially stops moving food through on schedule, causing persistent nausea and vomiting.⁴ The recommended stepwise titration exists for exactly this reason.

Rare but Serious Risks

Beyond everyday GI discomfort, there are a handful of uncommon but potentially serious adverse events worth knowing about.

Pancreatitis

Inflammation of the pancreas is one of the most closely watched risks with GLP-1 drugs. Pharmacovigilance data suggest that semaglutide carries a meaningful signal for pancreatitis, and that this risk extends to people without diabetes who use it for weight loss. One analysis found roughly a nine-fold increased risk of pancreatitis in non-diabetic people with obesity using GLP-1 drugs compared to those using a different weight-loss medication.⁵ That sounds alarming, but it is important context that pancreatitis remains uncommon in absolute terms. Still, if you develop severe abdominal pain that radiates to your back, especially in the first months of treatment, it needs prompt medical evaluation.

Thyroid Cancer

Semaglutide carries a boxed warning about thyroid tumors because it caused them in rodent studies. Human data have been harder to pin down. A systematic review looking across ten studies found that thyroid cancer cases were rare, each making up less than one percent of study participants, and concluded there was no significant risk signal.⁶ However, a separate analysis of the FDA’s adverse event reporting database found a statistically elevated reporting odds ratio for thyroid cancer with semaglutide.⁷ These two types of evidence are measuring different things; the clinical trial data track actual cancer diagnoses, while adverse event databases capture spontaneous reports, which can be inflated by awareness and media coverage. The prevailing view is that the absolute risk in humans appears very low, but people with a personal or family history of medullary thyroid carcinoma or a related condition called MEN 2 should not take the drug.

Gallbladder Problems

Rapid weight loss from any cause increases the risk of gallstones, and semaglutide is no exception. In the adolescent STEP TEENS trial, gallstones occurred in about four percent of participants on semaglutide, compared to none on placebo.⁸ This is something to watch for regardless of age.

The Cardiovascular Upside

If the risks section sounds concerning, this is where the balance tips. Wegovy is one of the few weight-loss medications that has demonstrated a genuine cardiovascular benefit in a rigorous outcomes trial. The SELECT trial enrolled over 17,000 adults with obesity and established cardiovascular disease but without diabetes. Participants on semaglutide had a roughly 20 percent lower rate of major adverse cardiovascular events, a composite of heart attack, stroke, and cardiovascular death, compared to placebo.⁹ That benefit was consistent regardless of participants’ baseline blood pressure.¹⁰

For many people with obesity who already have heart disease, the cardiovascular protection is not just a pleasant side benefit. It may be the primary medical reason to consider the drug, with weight loss being the mechanism through which those cardiovascular gains occur.

Benefits Beyond Weight Loss

The metabolic ripple effects of semaglutide extend beyond the heart. In the FLOW trial, which studied patients with type 2 diabetes and chronic kidney disease, semaglutide at 1 mg weekly reduced major kidney disease events by about 24 percent and slowed the decline in kidney function.¹¹ A phase 3 trial in patients with fatty liver disease and fibrosis showed that nearly 63 percent of those on semaglutide saw resolution of liver inflammation without worsening scarring, compared to about 34 percent on placebo.¹¹ These are meaningful results for conditions that historically have had very few effective drug treatments.

What About Mental Health?

Reports of depression, anxiety, and suicidal thoughts in people taking GLP-1 drugs attracted media attention and prompted regulatory scrutiny. The evidence here is genuinely mixed, and researchers have not reached a consensus.

On the reassuring side, a post hoc analysis of the STEP 1, 2, 3, and 5 trials found no meaningful differences in depression scores or suicidal ideation between participants on semaglutide and those on placebo, with one percent or fewer in either group reporting any suicidal ideation or behavior.¹² A large real-world cohort study went further, finding that semaglutide was associated with lower risk of suicidal ideation compared to other anti-obesity medications.¹³

On the more cautionary side, analyses of the FDA’s adverse event database have flagged signals. One study found elevated reporting odds for both depression and suicide-related events specifically with semaglutide, particularly in adults aged 18 to 64.¹⁴ Another found increased hazard ratios for major depressive disorder, anxiety, and suicidal ideation or attempts in people on GLP-1 drugs over time.¹⁵

How to make sense of this? Clinical trials are tightly controlled but often exclude people with significant psychiatric histories, which may underestimate real-world risk. Adverse event databases capture a broader population but are prone to reporting bias, especially when a drug is the subject of public controversy. The most prudent reading is that there is no clear evidence semaglutide causes psychiatric harm in people without pre-existing conditions, but anyone with a history of depression or suicidal ideation should be monitored closely while taking it.

Muscle Loss and Bone Health

Losing a large amount of weight on any drug or diet means losing some lean mass along with the fat. In the SEMALEAN study, participants lost about 3 kg of lean mass in the first seven months on semaglutide, though that loss stabilized afterward. The proportion of lean mass relative to total body weight actually went up over time, because fat was being lost faster.¹⁶ Resistance exercise and adequate protein intake are the standard recommendations to blunt this effect, and clinicians increasingly emphasize them alongside the prescription.

Bone health is a newer concern, especially for older adults. Data from the SELECT trial revealed higher rates of hip and pelvic fractures among women on semaglutide compared to placebo, and also higher rates in participants over age 75.¹⁷ A small pilot study in older adults did not find a significant difference in bone mineral density between those on semaglutide plus lifestyle counseling and those on lifestyle counseling alone, but the study lasted only 20 weeks, which may not be long enough to capture the effect.¹⁸ Falls are also a concern: an analysis of FDA adverse event reports found that fall-related events were nearly three times as commonly reported in older patients taking GLP-1 drugs compared to younger ones.¹⁹

Special Situations

Teenagers

Wegovy has been studied in adolescents (ages 12 and older) and is approved for use in this group. In the STEP TEENS trial, GI side effects were more common than in adults, affecting about 62 percent of those on semaglutide compared to 42 percent on placebo. Despite this, the dropout rate due to side effects was the same in both groups, about five percent.²⁰ No cases of pancreatitis occurred in the trial, though pancreatic enzyme levels did tick up in the semaglutide group. The overall assessment from researchers was that no new safety issues emerged in teenagers.²¹

Pregnancy and Fertility

Semaglutide should be stopped before trying to conceive. Animal studies indicate potential fetal risks, and human data are limited. Because semaglutide has a long half-life (about a week), guidelines recommend discontinuing it at least 35 days before conception to allow adequate clearance from the body.²² Limited observational data so far have not shown a significant increase in birth defects with inadvertent early exposure, but the evidence base remains thin.²³ One wrinkle worth knowing: semaglutide can improve ovulation in women with obesity-related hormonal imbalances, which means unintended pregnancy is a real possibility during treatment, especially for women who were previously not ovulating regularly.

Older Adults

People over 65, and especially over 75, face a somewhat different risk-benefit calculation. The cardiovascular benefits remain relevant, and arguably more so given the higher baseline risk. But the lean-mass loss and fracture signals mentioned earlier are more consequential in a population already prone to sarcopenia and osteoporosis. Careful monitoring of bone health, nutritional status, and fall risk is essential for older patients on semaglutide.

Nutritional Gaps That Develop Over Time

Because semaglutide reduces appetite and total food intake, it can create nutritional shortfalls that build gradually. A narrative review found that vitamin D deficiency was the most common issue, affecting about 7.5 percent of users at six months and nearly 14 percent at 12 months. Iron stores were notably lower in GLP-1 drug users, with ferritin levels 26 to 30 percent below those of people on a different medication class. Over 60 percent of users consumed below the estimated dietary requirements for calcium and iron, and average vitamin D intake was only about a fifth of recommendations.²⁴ Protein insufficiency contributed to lean mass loss, and deficiencies in thiamine and vitamin B12 increased over time. These are not dramatic side effects, but they compound. Anyone staying on semaglutide long-term should be thinking about dietary quality and potentially supplementation, not just calorie reduction.

What Happens When You Stop

This may be the most underappreciated safety-adjacent issue. Semaglutide is not a cure for obesity; it is an ongoing treatment. In the STEP 1 extension study, participants who stopped the drug after 68 weeks regained an average of about 12 percentage points of body weight over the following year. Improvements in blood pressure, cholesterol, and inflammatory markers also reversed, though some lipid benefits lingered compared to the placebo group.²⁵ Broader modeling data suggest that 60 to 90 percent of lost weight returns within a year of stopping, and metabolic markers like blood sugar, blood pressure, and lipids drift back to their pre-treatment levels within about 12 months.²⁶

This means the safety question is not just “is it safe to take Wegovy” but “is it safe to take Wegovy indefinitely,” because that is what the drug’s mechanism effectively demands for sustained results. Long-term adherence data paint a challenging picture. One large insurance claims analysis found that only about a third of people were still taking semaglutide at one year, though persistence rates have been improving over time, reaching nearly 59 percent among people who started in the first half of 2024.²⁷ Cost, insurance coverage, and supply disruptions are the usual culprits behind discontinuation, alongside side effects.

Eye Health in People With Diabetes

If you have diabetes, there is a specific risk worth understanding. A meta-analysis found that semaglutide overall does not increase or decrease the risk of eye disorders or diabetic retinopathy.²⁸ But the story is more nuanced for people with pre-existing diabetic retinopathy. Data from the SUSTAIN-6 trial, a cardiovascular outcomes study in diabetes, showed a higher rate of retinopathy complications with semaglutide, especially in patients who already had eye damage. The likely culprit is the rapid drop in blood sugar rather than any direct effect on the retina. This “early worsening” phenomenon is a recognized risk with any treatment that sharply improves blood glucose control in people with diabetes.²⁹ For people using Wegovy purely for weight loss without diabetes, this is largely a non-issue. For those with diabetes and existing retinopathy, it means eye exams should be part of the monitoring plan.

Compounded Semaglutide Is a Different Question

With Wegovy’s high cost and periodic supply shortages, compounded versions of semaglutide became widely available through telehealth platforms and compounding pharmacies. The safety of these products is materially different from the FDA-approved brand. A pharmacovigilance analysis of the FDA adverse event database found that compounded formulations were associated with higher odds of several serious events, including suicidality (about six times higher), cholecystitis (about three times higher), and hospitalization (more than twice as likely) compared to the brand-name products. Compounded versions also had dramatically higher rates of preparation errors and contamination reports.³⁰ The FDA has warned consumers about the risks of compounded semaglutide, and anyone considering a non-brand alternative should understand that the clinical trial safety data discussed throughout this article apply to the manufactured product, not to compounded copies.

Surgery and Anesthesia

If you are scheduled for any procedure requiring anesthesia or sedation, the fact that semaglutide slows gastric emptying becomes relevant. Food that has been sitting in your stomach longer than expected raises the risk of aspiration (inhaling stomach contents into the lungs) during sedation. Meta-analyses involving over 300,000 patients have found that retained gastric contents are significantly more common in people on GLP-1 drugs. However, actual pulmonary aspiration rates remain very low, in the range of 0.1 to 0.2 percent, and were not significantly higher than in control groups.³¹ Most anesthesiology guidelines now recommend holding GLP-1 drugs for a period before elective surgery, and you should tell your anesthesiologist that you take Wegovy well in advance of any planned procedure.